Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | EVP & Chief Info Officer | August 10, 2016 | August 10, 2016 |
| Zapata Quantum, Inc.ZPTA · Entity 6486 | Director | May 01, 2026 | May 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date August 10, 2016 · Filed August 10, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,083 |
Reported balance
After 2016-08-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-08-10 · Sale · Disposed 3,000 · Balance 14,083 F1: Holdings include shares acquired in dividend reinvestment transactions. |
| Common Stock - 401(k) PlanSEC Table I · non-derivative | IndirectBy 401(k) | 5,859.5439 |
Reported balance
Holding disclosure · report date 2016-08-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,859.5439 F2: Holdings include shares acquired and dividends earned through July 8, 2016, in the Merck U.S. Savings Plan, a 401(k) plan. In addition, since the date of the reporting person's last ownership report, shares of Merck & Co., Inc. common stock within the 401(k) plan were disposed pursuant to a domestic relations order. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include shares acquired in dividend reinvestment transactions.
F2: Holdings include shares acquired and dividends earned through July 8, 2016, in the Merck U.S. Savings Plan, a 401(k) plan. In addition, since the date of the reporting person's last ownership report, shares of Merck & Co., Inc. common stock within the 401(k) plan were disposed pursuant to a domestic relations order.
Zapata Quantum, Inc.
Report date May 01, 2026 · Filed May 07, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,626,288 |
Reported balance
Holding disclosure · report date 2026-05-01 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 32,626,288 F1: 32,500,000 of the shares of restricted stock vest in equal monthly installments over a two-year period. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2031-02-04 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-01 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance Not disclosed F2: 100% of the shares subject to the option are fully vested and exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2033-07-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-01 · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · Balance Not disclosed F3: The stock options are fully vested and exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.08 · Expires 2030-10-09 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-01 · row 7
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 7 · Balance Not disclosed F6: The grant of stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The stock options shall vest in equal monthly increments over two years, with the first vesting date to occur on November 9, 2025, subject to continued service as a director of the Issuer on each applicable vesting date and the execution of the Issuer's Stock Option Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-01 · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · Balance Not disclosed F4: Restricted stock units convert into shares of common stock on a one-for-one basis. The restricted stock units will vest in three equal installments, with 25,000 shares of common stock vesting on October 10, 2024, 25,000 shares of common stock vesting on January 10, 2025, and 25,000 shares vesting on the date of the 2025 annual meeting of the Issuer's stockholders. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2026-06-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-01 · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · Balance Not disclosed F5: The Reporting Person purchased a convertible promissory note in the principal amount of $100,000 and an accompanying five-year warrant to purchase 1,250,000 shares of common stock, for a total purchase price of $100,000. The conversion price of the note and exercise price of the warrant are each $0.04 per share. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2030-06-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-01 · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · Balance Not disclosed F5: The Reporting Person purchased a convertible promissory note in the principal amount of $100,000 and an accompanying five-year warrant to purchase 1,250,000 shares of common stock, for a total purchase price of $100,000. The conversion price of the note and exercise price of the warrant are each $0.04 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: 32,500,000 of the shares of restricted stock vest in equal monthly installments over a two-year period.
F2: 100% of the shares subject to the option are fully vested and exercisable.
F3: The stock options are fully vested and exercisable.
F4: Restricted stock units convert into shares of common stock on a one-for-one basis. The restricted stock units will vest in three equal installments, with 25,000 shares of common stock vesting on October 10, 2024, 25,000 shares of common stock vesting on January 10, 2025, and 25,000 shares vesting on the date of the 2025 annual meeting of the Issuer's stockholders.
F5: The Reporting Person purchased a convertible promissory note in the principal amount of $100,000 and an accompanying five-year warrant to purchase 1,250,000 shares of common stock, for a total purchase price of $100,000. The conversion price of the note and exercise price of the warrant are each $0.04 per share.
F6: The grant of stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The stock options shall vest in equal monthly increments over two years, with the first vesting date to occur on November 9, 2025, subject to continued service as a director of the Issuer on each applicable vesting date and the execution of the Issuer's Stock Option Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2025 Filed Oct 10, 2025 20:38 UTC | Zapata Quantum, Inc. ZPTA · Entity 6486 | GrantStock Options (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $0.08 | $0.00 |
DisclosureSEC source: 0001079973-25-001592 · ownership.xml · derivative · entry 1 Golestani Clark · CIK 0001563786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2030-10-09 F1 · derivative.exercise_date: The grant of stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The stock options shall vest in equal monthly increments over two years, with the first vesting date to occur on November 9, 2025, subject to continued service as a director of the Issuer on each applicable vesting date and the execution of the Issuer's Stock Option Agreement. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 20:07 UTC | Zapata Quantum, Inc. ZPTA · Entity 6486 | GrantCommon Stock | 32,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-25-001035 · ownership.xml · nonDerivative · entry 1 Golestani Clark · CIK 0001563786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,626,288 F1 · security: The shares of restricted stock vest in equal monthly installments over a two-year period. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:07 UTC | Zapata Quantum, Inc. ZPTA · Entity 6486 | PurchaseWarrant · Derivative | 1,250,000 | Not disclosed Strike: $0.04 | Not disclosed |
DisclosureSEC source: 0001079973-25-001035 · ownership.xml · derivative · entry 3 Golestani Clark · CIK 0001563786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires 2030-06-12 F2 · security: The reporting person purchased a convertible promissory note in the principal amount of $100,000 and an accompanying five-year warrant to purchase 1,250,000 shares of common stock, for a total purchase price of $100,000. The conversion price of the note and exercise price of the warrant are each $0.04 per share. F2 · price: The reporting person purchased a convertible promissory note in the principal amount of $100,000 and an accompanying five-year warrant to purchase 1,250,000 shares of common stock, for a total purchase price of $100,000. The conversion price of the note and exercise price of the warrant are each $0.04 per share. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:07 UTC | Zapata Quantum, Inc. ZPTA · Entity 6486 | PurchaseConvertible Promissory Note · Derivative | Not disclosed | $100,000.00 Strike: $0.04 | $100,000.00 |
DisclosureSEC source: 0001079973-25-001035 · ownership.xml · derivative · entry 2 Golestani Clark · CIK 0001563786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 2,500,000 shares Expires 2026-06-12 F2 · security: The reporting person purchased a convertible promissory note in the principal amount of $100,000 and an accompanying five-year warrant to purchase 1,250,000 shares of common stock, for a total purchase price of $100,000. The conversion price of the note and exercise price of the warrant are each $0.04 per share. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 22:09 UTC | Zapata Quantum, Inc. ZPTA · Entity 6486 | GrantRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-013687 · form4.xml · derivative · entry 2 Golestani Clark · CIK 0001563786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into shares of common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units will vest in three equal installments, with 25,000 shares of common stock vesting on October 10, 2024, 25,000 shares of common stock vesting on January 10, 2025, and 25,000 shares vesting on the date of the 2025 annual meeting of the Issuer's stockholders. F2 · derivative.expiration_date: The restricted stock units will vest in three equal installments, with 25,000 shares of common stock vesting on October 10, 2024, 25,000 shares of common stock vesting on January 10, 2025, and 25,000 shares vesting on the date of the 2025 annual meeting of the Issuer's stockholders. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 22:09 UTC | Zapata Quantum, Inc. ZPTA · Entity 6486 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-013687 · form4.xml · nonDerivative · entry 1 Golestani Clark · CIK 0001563786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,288 Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 13:24 UTC | Zapata Quantum, Inc. ZPTA · Entity 6486 | GrantStock Option (Right to Buy) · Derivative | 68,558 | Not disclosed Strike: $3.80 | Not disclosed |
DisclosureSEC source: 0001062993-24-007520 · form4.xml · derivative · entry 3 Golestani Clark · CIK 0001563786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,558 Underlying: Common Stock · 68,558 shares Expires 2033-07-31 F5 · price: Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 75,000 shares of common stock of Private Zapata at a purchase price of $3.47 per share. F4 · derivative.exercise_date: The option became or will become exercisable in equal annual installments over two years from September 16, 2022. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 13:24 UTC | Zapata Quantum, Inc. ZPTA · Entity 6486 | GrantStock Option (Right to Buy) · Derivative | 34,279 | Not disclosed Strike: $2.02 | Not disclosed |
DisclosureSEC source: 0001062993-24-007520 · form4.xml · derivative · entry 2 Golestani Clark · CIK 0001563786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,279 Underlying: Common Stock · 34,279 shares Expires 2031-02-04 F3 · price: Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 37,500 shares of common stock of Private Zapata at a purchase price of $1.84 per share. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 13:24 UTC | Zapata Quantum, Inc. ZPTA · Entity 6486 | GrantCommon Stock | 101,288 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-24-007520 · form4.xml · nonDerivative · entry 1 Golestani Clark · CIK 0001563786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,288 F1 · price: Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of September 6, 2023, by and among Andretti Acquisition Corp., Tigre Merger Sub, Inc. and Zapata Computing, Inc. ("Private Zapata"), in exchange for 110,805 shares of common stock of Private Zapata. Read SEC document |
| August 10, 2016 Filed Aug 10, 2016 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 3,000 | $63.03 | $189,090.00 |
DisclosureSEC source: 0001225208-16-037707 · doc4.xml · nonDerivative · entry 1 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,083 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 20, 2016 Filed May 20, 2016 18:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 38,647 | $0.00 Strike: $44.98 | $0.00 |
DisclosureSEC source: 0001225208-16-033678 · doc4.xml · derivative · entry 5 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,647 shares Expires 2023-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016. Read SEC document |
| May 20, 2016 Filed May 20, 2016 18:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 38,647 | $54.80 | $2,117,855.60 |
DisclosureSEC source: 0001225208-16-033678 · doc4.xml · nonDerivative · entry 3 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,083 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 20, 2016 Filed May 20, 2016 18:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 38,647 | $44.98 | $1,738,342.06 |
DisclosureSEC source: 0001225208-16-033678 · doc4.xml · nonDerivative · entry 2 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2016 Filed May 20, 2016 18:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 1,230 | $54.55 | $67,096.50 |
DisclosureSEC source: 0001225208-16-033678 · doc4.xml · nonDerivative · entry 1 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,083 Read SEC document |
| May 10, 2016 Filed May 12, 2016 15:39 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 50,934 | $0.00 Strike: $54.68 | $0.00 |
DisclosureSEC source: 0001225208-16-033207 · doc4.xml · derivative · entry 3 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,934 Underlying: Common Stock · 50,934 shares Expires 2026-05-09 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| February 22, 2016 Filed Feb 24, 2016 17:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 6,150 | $50.77 | $312,235.50 |
DisclosureSEC source: 0001225208-16-027761 · doc4.xml · nonDerivative · entry 1 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,313 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance share units granted on 03/29/2013. Performance shares were paid out at 105 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 2,275 | $0.00 Strike: $45.85 | $0.00 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · derivative · entry 17 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,275 shares Expires 2016-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option became exercisable in equal installments on 11/1/2007, 11/1/2008 and 11/1/2009. Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 2,602 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · derivative · entry 16 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,602 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option became exercisable in equal installments on 5/7/2011, 5/7/2012 and 5/7/2013. Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 8,085 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · derivative · entry 15 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,085 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2012, 5/4/2013, 5/4/2014. Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 14,260 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · derivative · entry 14 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,260 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 3,120 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · derivative · entry 13 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,120 shares Expires 2017-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 3/2/2008, 3/2/2009 and 3/2/2010. Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $44.30 | $0.00 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · derivative · entry 12 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,200 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 2/28/2009, 2/28/2010 and 2/28/2011. Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 30,065 | $59.09 | $1,776,652.09 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · nonDerivative · entry 10 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,163.12 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.0600 to $59.1250, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Since the date of the reporting person's last ownership report, Mr. Golestani transferred 953 shares of common stock of Merck & Co., Inc. to his former spouse pursuant to a domestic relations order. Holding also include shares acquired in dividend reinvestment transactions. Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 912 | $58.98 | $53,787.02 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · nonDerivative · entry 9 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,228.12 Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 838 | $58.98 | $49,421.80 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · nonDerivative · entry 8 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,140.12 Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 16 | $58.98 | $943.68 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · nonDerivative · entry 7 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,978.12 Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 2,275 | $45.85 | $104,308.75 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · nonDerivative · entry 6 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,994.12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 2,602 | $33.49 | $87,140.98 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · nonDerivative · entry 5 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,719.12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,120 | $44.19 | $137,872.80 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · nonDerivative · entry 4 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,117.12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 5,200 | $44.30 | $230,360.00 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · nonDerivative · entry 3 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,997.12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 8,085 | $36.56 | $295,587.60 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · nonDerivative · entry 2 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,797.12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2015 Filed Aug 4, 2015 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 14,260 | $39.29 | $560,275.40 |
DisclosureSEC source: 0001225208-15-016368 · doc4.xml · nonDerivative · entry 1 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,712.12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 2,291 | $59.86 | $137,139.26 |
DisclosureSEC source: 0001225208-15-011275 · doc4.xml · derivative · entry 5 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,291 shares Expires 2015-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 02, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 854 | $59.86 | $51,120.44 |
DisclosureSEC source: 0001225208-15-011275 · doc4.xml · nonDerivative · entry 2 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,405.12 F1 · balance_after: Since the date of the reporting person's last ownership report, Mr. Golestani transferred 2,012 shares of common stock of Merck & Co., Inc. to his former spouse pursuant to a domestic relations order. The reporting person will no longer report as beneficially owned any security owned by his former spouse. Holdings also include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 2,291 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-15-011275 · doc4.xml · nonDerivative · entry 1 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,259.12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 46,440 | $0.00 Strike: $59.86 | $0.00 |
DisclosureSEC source: 0001225208-15-011275 · doc4.xml · derivative · entry 4 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,440 Underlying: Common Stock · 46,440 shares Expires 2025-04-30 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. Read SEC document |
| February 23, 2015 Filed Feb 25, 2015 16:27 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 1,466 | $58.30 | $85,467.80 |
DisclosureSEC source: 0001225208-15-005605 · doc4.xml · nonDerivative · entry 1 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,980.12 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/30/2012. Performance shares were paid out at 102 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 41,265 | $0.00 Strike: $58.22 | $0.00 |
DisclosureSEC source: 0001225208-14-012818 · doc4.xml · derivative · entry 4 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,265 Underlying: Common Stock · 41,265 shares Expires 2024-05-08 F3 · derivative.exercise_date: The option vests in three equal annual installments beginning May 9, 2015. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 2,051 | $58.22 | $119,409.22 |
DisclosureSEC source: 0001225208-14-012266 · doc4.xml · derivative · entry 5 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,051 shares Expires 2014-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 764 | $58.22 | $44,480.08 |
DisclosureSEC source: 0001225208-14-012266 · doc4.xml · nonDerivative · entry 2 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,514.12 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 2,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-012266 · doc4.xml · nonDerivative · entry 1 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,278.12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2014 Filed Feb 26, 2014 19:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 1,181 | $56.18 | $66,348.58 |
DisclosureSEC source: 0001225208-14-006331 · doc4.xml · nonDerivative · entry 1 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,227.12 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/31/2011. Performance shares were paid out at 86 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 14, 2014 Filed Feb 14, 2014 22:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 6,375 | $0.00 Strike: $48.24 | $0.00 |
DisclosureSEC source: 0001225208-14-004670 · doc4.xml · derivative · entry 6 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,375 shares Expires 2014-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2014 Filed Feb 14, 2014 22:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 4,800 | $55.47 | $266,267.04 |
DisclosureSEC source: 0001225208-14-004670 · doc4.xml · nonDerivative · entry 3 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,046.12 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 14, 2014 Filed Feb 14, 2014 22:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 1,190 | $55.47 | $66,009.30 |
DisclosureSEC source: 0001225208-14-004670 · doc4.xml · nonDerivative · entry 2 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,846.12 Read SEC document |
| February 14, 2014 Filed Feb 14, 2014 22:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 6,375 | $48.24 | $307,530.00 |
DisclosureSEC source: 0001225208-14-004670 · doc4.xml · nonDerivative · entry 1 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,036.12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 2,239 | $44.98 | $100,710.22 |
DisclosureSEC source: 0001225208-13-011730 · doc4.xml · derivative · entry 6 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,239 shares Expires 2013-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 835 | $44.98 | $37,558.30 |
DisclosureSEC source: 0001225208-13-011730 · doc4.xml · nonDerivative · entry 2 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,648.835 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 2,239 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-011730 · doc4.xml · nonDerivative · entry 1 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,483.835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 38,647 | $0.00 Strike: $44.98 | $0.00 |
DisclosureSEC source: 0001225208-13-011730 · doc4.xml · derivative · entry 5 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,647 Underlying: Common Stock · 38,647 shares Expires 2023-05-05 F3 · derivative.exercise_date: The option vests in three equal annual installments beginning May 6, 2014. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.